David J Maron, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Maron’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G48267 · Current
Licensed to practise in California · since 1982 · expires 2027-11-30 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Tennessee 24919Medical Doctor · since 1993 · expires 2014-11-30Specialty on the licence: Cardiovascular DiseasesVoluntarily RetiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
4 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- Univ of Southern CA · MDLOS ANGELES CA · 1981Medical school
Residency and fellowship
- Fellowship CardiologySTANFORD CA USA · 1989–1991
- Fellowship Robt Wood Johnson FellowSTANFORD CA USA · 1984–1986
- Residency UCLALOS ANGELES CA USA · 1982–1984
- Internship Internal Medicine UCLALOS ANGELES CA USA · 1981–1982
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$26,873
Medicare paid this office $26,873 for 279 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 52 | $8,446 | $156 |
| New patient visit (60+ min) | 23 | $4,810 | $209 |
| Return visit (30+ min) | 29 | $3,170 | $106 |
| Long return visit (40+ min) | 14 | $1,787 | $128 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,618 | $70 |
See all 9 services
| Long return visit (40+ min) | 52 | $8,446 | $156 |
| New patient visit (60+ min) | 23 | $4,810 | $209 |
| Return visit (30+ min) | 29 | $3,170 | $106 |
| Long return visit (40+ min) | 14 | $1,787 | $128 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,618 | $70 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $1,569 | $44 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $1,305 | $69 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 101 | $849 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 21 | $479 | $23 |
Who their Medicare patients are
279 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 46% · Also on Medicaid 21% · Health risk score 1.49. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 59% · Atrial fibrillation 37% · Heart failure 34% · Chronic kidney disease 33% · Diabetes 32% · Depression 20% · Cancer 16% · COPD 14% · Stroke 13% · Dementia 8%.
The office billed $145,263, Medicare allowed $35,958 and paid $26,873; for 373 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 279 | 373 | 75 | 1.49 | $145,263 | $26,873 |
| 2023 | 167 | 271 | 76 | 1.27 | $138,782 | $22,342 |
| 2022 | 471 | 621 | 73 | 2.16 | $136,759 | $22,128 |
| 2021 | 249 | 396 | 74 | 1.65 | $134,469 | $23,239 |
| 2020 | 389 | 475 | 74 | 2.26 | $89,452 | $13,422 |
| 2019 | 306 | 386 | 74 | 1.81 | $40,616 | $13,579 |
| 2018 | 253 | 364 | 74 | 1.69 | $50,779 | $16,342 |
| 2017 | 618 | 780 | 72 | 1.94 | $81,885 | $18,392 |
| 2016 | 375 | 505 | 73 | 1.73 | $77,015 | $17,851 |
| 2015 | 125 | 196 | 72 | 1.71 | $51,096 | $13,671 |
| 2014 | 90 | 151 | 71 | 1.45 | $40,390 | $10,834 |
| 2013 | 431 | 485 | 69 | 2.08 | $31,840 | $6,992 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Long return visit (40+ min) | 48 | $6,278 | $116 |
| New patient visit (60+ min) | 24 | $3,340 | $139 |
| Return visit (30+ min) | 36 | $2,623 | $71 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $1,927 | $45 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,746 | $76 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,204 | $75 |
| New patient visit (45+ min) | 11 | $1,126 | $102 |
| Short return visit (20+ min) | 12 | $712 | $59 |
2022: 9 services
| Long return visit (40+ min) | 37 | $4,540 | $108 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 315 | $2,753 | $8 |
| New patient visit (45+ min) | 18 | $1,982 | $110 |
| Return visit (30+ min) | 20 | $1,951 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,103 | $65 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,090 | $35 |
| Hospital discharge day management, 30 minutes or less | 15 | $1,066 | $67 |
| Short return visit (20+ min) | 13 | $546 | $42 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 20 | $521 | $25 |
2021: 12 services
| Long return visit (40+ min) | 39 | $5,695 | $124 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,287 | $127 |
| New patient visit (60+ min) | 13 | $2,139 | $165 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,451 | $35 |
| Return visit (30+ min) | 16 | $1,393 | $82 |
| New patient visit (45+ min) | 13 | $1,390 | $107 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,223 | $68 |
| Short return visit (20+ min) | 17 | $1,075 | $57 |
| Hospital observation care on day of discharge | 13 | $968 | $69 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 106 | $883 | $8 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 12 | $540 | $30 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 17 | $432 | $25 |
2020: 5 services
| Return visit (30+ min) | 41 | $3,309 | $66 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 256 | $2,082 | $7 |
| New patient visit (45+ min) | 19 | $1,716 | $90 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 33 | $753 | $23 |
| Short return visit (20+ min) | 13 | $509 | $36 |
2019: 4 services
| Return visit (30+ min) | 58 | $4,996 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 180 | $1,550 | $8 |
| Long return visit (40+ min) | 11 | $1,266 | $97 |
| Short return visit (20+ min) | 13 | $511 | $36 |
2018: 7 services
| Return visit (30+ min) | 43 | $4,034 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,344 | $122 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,337 | $67 |
| New patient visit (15+ min) | 22 | $952 | $43 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 112 | $925 | $7 |
| Short return visit (20+ min) | 17 | $737 | $41 |
| Ambulatory blood pressure monitoring, 1 day or longer, with review, interpretation and report | 12 | $222 | $17 |
2017: 8 services
| Return visit (30+ min) | 51 | $4,758 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 466 | $3,864 | $7 |
| New patient visit (45+ min) | 16 | $1,583 | $99 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,256 | $90 |
| Hospital discharge day management, 30 minutes or less | 13 | $861 | $66 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 27 | $661 | $24 |
| Short return visit (20+ min) | 11 | $456 | $41 |
| Ambulatory blood pressure monitoring, 1 day or longer, with review, interpretation and report | 12 | $204 | $17 |
2016: 6 services
| Return visit (30+ min) | 39 | $3,963 | $62 |
| New patient visit (45+ min) | 24 | $2,478 | $103 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 209 | $1,799 | $7 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 45 | $1,055 | $23 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $1,046 | $35 |
| Hospital discharge day management, 30 minutes or less | 12 | $724 | $60 |
2015: 4 services
| Return visit (30+ min) | 25 | $3,008 | $67 |
| New patient visit (45+ min) | 28 | $3,004 | $107 |
| New patient visit (60+ min) | 14 | $2,096 | $150 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 46 | $1,106 | $24 |
2014: 6 services
| New patient visit (60+ min) | 11 | $1,645 | $150 |
| Return visit (30+ min) | 13 | $1,538 | $70 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,461 | $122 |
| New patient visit (30+ min) | 12 | $810 | $68 |
| Hospital discharge day management, 30 minutes or less | 11 | $786 | $65 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 30 | $726 | $24 |
2013: 2 services
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 352 | $2,232 | $6 |
| Return visit (30+ min) | 29 | $1,679 | $51 |
Medicaid work
$276 in 2024
Medicaid paid $276 for 35 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 35 | $276 |
| 2024 | 35 | 1 | 34 | $276 |
| 2022 | 296 | 1 | 129 | $3,487 |
| 2021 | 90 | 1 | 83 | $1,173 |
| 2020 | 244 | 1 | 77 | $3,074 |
| 2019 | 112 | 1 | 58 | $1,339 |
| 2018 | 72 | 1 | 62 | $630 |
See the largest Medicaid services in earlier years
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 296 | $3,487 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 90 | $1,173 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 244 | $3,074 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 112 | $1,339 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 72 | $630 |
Drugs they prescribed that Part D paid
$188,014
Pharmacies billed $188,014 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 965) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
792 generic and fewer than 11 brand-name prescriptions · $188,014 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Repatha Sureclick | 86 | $79,692 | $927 |
| Eliquis | 22 | $37,069 | $1,685 |
| Jardiance | 13 | $19,517 | $1,501 |
| Praluent | 13 | $7,279 | $560 |
| Rosuvastatin | 147 | $3,190 | $22 |
See all 20 drugs
| Repatha Sureclick | 86 | $79,692 | $927 |
| Eliquis | 22 | $37,069 | $1,685 |
| Jardiance | 13 | $19,517 | $1,501 |
| Praluent | 13 | $7,279 | $560 |
| Rosuvastatin | 147 | $3,190 | $22 |
| Ezetimibe | 114 | $3,052 | $27 |
| Colchicine | 16 | $1,523 | $95 |
| Atorvastatin | 86 | $1,002 | $12 |
| Carvedilol | 34 | $661 | $19 |
| Metoprolol | 51 | $645 | $13 |
| Amlodipine Besylate | 91 | $560 | $6 |
| Clopidogrel | 22 | $315 | $14 |
| Lisinopril | 33 | $244 | $7 |
| Chlorthalidone | 12 | $212 | $18 |
| Nitroglycerin | 20 | $207 | $10 |
| Losartan | 24 | $206 | $9 |
| Isosorbide Mononitrate Er | 17 | $168 | $10 |
| Spironolactone | 27 | $143 | $5 |
| Hydrochlorothiazide | 17 | $66 | $4 |
| Losartan-Hydrochlorothiazide | 19 | $62 | $3 |
Year by year
| 2024 | 965 | 159 | 0% (0) | None | $188,014 |
| 2023 | 933 | 128 | 0% (0) | 19% | $214,073 |
| 2022 | 856 | 121 | 0% (0) | 20% | $187,634 |
| 2021 | 759 | 109 | 0% (0) | 20% | $132,074 |
| 2020 | 596 | 98 | 0% (0) | 16% | $82,770 |
| 2019 | 512 | 83 | 0% (0) | 15% | $62,405 |
| 2018 | 554 | 121 | 0% (0) | 18% | $103,613 |
| 2017 | 652 | 125 | 0% (0) | 23% | $135,282 |
| 2016 | 495 | 93 | 0% (0) | 21% | $55,309 |
| 2015 | 310 | 56 | 0% (0) | 16% | $14,416 |
| 2014 | 166 | 39 | 0% (0) | 22% | $8,292 |
| 2013 | 242 | 37 | None | 31% | $23,251 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Repatha Sureclick | 50 | $58,641 | $1,173 |
| Eliquis | 20 | $36,676 | $1,834 |
| Praluent | 33 | $29,625 | $898 |
| Jardiance | 11 | $19,180 | $1,744 |
| Vascepa | 20 | $8,684 | $434 |
| Repatha | 13 | $7,997 | $615 |
| Ezetimibe | 88 | $4,569 | $52 |
| Rosuvastatin | 116 | $3,693 | $32 |
| Colchicine | 17 | $3,221 | $189 |
| Atorvastatin | 102 | $1,400 | $14 |
| Carvedilol | 41 | $907 | $22 |
| Metoprolol | 34 | $848 | $25 |
| Chlorthalidone | 17 | $763 | $45 |
| Amlodipine Besylate | 95 | $748 | $8 |
| Clopidogrel | 23 | $511 | $22 |
| Lisinopril | 46 | $489 | $11 |
| Losartan | 26 | $240 | $9 |
| Losartan-Hydrochlorothiazide | 11 | $218 | $20 |
| Nitroglycerin | 11 | $185 | $17 |
| Simvastatin | 11 | $178 | $16 |
| Spironolactone | 14 | $174 | $12 |
| Hydrochlorothiazide | 19 | $98 | $5 |
| Isosorbide Mononitrate Er | 16 | $67 | $4 |
2022: 23 drugs
| Repatha Sureclick | 54 | $51,490 | $954 |
| Eliquis | 22 | $29,561 | $1,344 |
| Xarelto | 13 | $20,189 | $1,553 |
| Jardiance | 12 | $15,259 | $1,272 |
| Praluent | 15 | $11,578 | $772 |
| Brilinta | 15 | $6,805 | $454 |
| Repatha | 12 | $6,668 | $556 |
| Vascepa | 13 | $6,452 | $496 |
| Rosuvastatin | 98 | $5,312 | $54 |
| Ezetimibe | 76 | $4,467 | $59 |
| Colchicine | 20 | $3,839 | $192 |
| Atorvastatin | 114 | $1,811 | $16 |
| Metoprolol | 27 | $590 | $22 |
| Amlodipine Besylate | 85 | $530 | $6 |
| Chlorthalidone | 15 | $449 | $30 |
| Clopidogrel | 24 | $412 | $17 |
| Lisinopril | 47 | $350 | $7 |
| Carvedilol | 22 | $335 | $15 |
| Simvastatin | 14 | $311 | $22 |
| Spironolactone | 19 | $264 | $14 |
| Losartan | 26 | $227 | $9 |
| Isosorbide Mononitrate Er | 16 | $165 | $10 |
| Metoprolol | 13 | $19 | $1 |
2021: 19 drugs
| Repatha Sureclick | 30 | $26,644 | $888 |
| Eliquis | 25 | $25,838 | $1,034 |
| Vascepa | 27 | $14,870 | $551 |
| Praluent | 26 | $13,027 | $501 |
| Brilinta | 12 | $5,196 | $433 |
| Ezetimibe | 75 | $4,259 | $57 |
| Rosuvastatin | 86 | $3,141 | $37 |
| Atorvastatin | 109 | $1,650 | $15 |
| Chlorthalidone | 12 | $489 | $41 |
| Clopidogrel | 24 | $433 | $18 |
| Metoprolol | 18 | $380 | $21 |
| Spironolactone | 30 | $275 | $9 |
| Amlodipine Besylate | 53 | $259 | $5 |
| Losartan | 17 | $244 | $14 |
| Lisinopril | 38 | $206 | $5 |
| Carvedilol | 22 | $148 | $7 |
| Simvastatin | 11 | $73 | $7 |
| Furosemide | 19 | $49 | $3 |
| Metoprolol | 14 | $31 | $2 |
2020: 13 drugs
| Repatha Sureclick | 21 | $11,989 | $571 |
| Xarelto | 12 | $11,505 | $959 |
| Vascepa | 18 | $7,104 | $395 |
| Ezetimibe | 75 | $6,764 | $90 |
| Rosuvastatin | 87 | $3,310 | $38 |
| Atorvastatin | 96 | $1,909 | $20 |
| Chlorthalidone | 12 | $542 | $45 |
| Metoprolol | 20 | $452 | $23 |
| Nitroglycerin | 19 | $426 | $22 |
| Losartan | 19 | $383 | $20 |
| Clopidogrel | 21 | $277 | $13 |
| Amlodipine Besylate | 35 | $217 | $6 |
| Lisinopril | 25 | $194 | $8 |
2019: 15 drugs
| Eliquis | 19 | $16,482 | $867 |
| Repatha Sureclick | 16 | $13,691 | $856 |
| Olmesartan-Hydrochlorothiazide | 11 | $3,373 | $307 |
| Ezetimibe | 52 | $3,108 | $60 |
| Rosuvastatin | 60 | $2,261 | $38 |
| Atorvastatin | 78 | $1,557 | $20 |
| Nitroglycerin | 18 | $475 | $26 |
| Chlorthalidone | 16 | $469 | $29 |
| Metoprolol | 11 | $422 | $38 |
| Clopidogrel | 24 | $396 | $16 |
| Lisinopril | 24 | $320 | $13 |
| Amlodipine Besylate | 34 | $248 | $7 |
| Losartan | 24 | $225 | $9 |
| Metoprolol | 15 | $144 | $10 |
| Spironolactone | 11 | $127 | $12 |
2018: 13 drugs
| Praluent | 45 | $54,811 | $1,218 |
| Eliquis | 11 | $8,575 | $780 |
| Rosuvastatin | 62 | $3,699 | $60 |
| Ezetimibe | 26 | $2,582 | $99 |
| Atorvastatin | 102 | $2,266 | $22 |
| Fluvastatin | 12 | $1,303 | $109 |
| Metoprolol | 17 | $459 | $27 |
| Isosorbide Mononitrate Er | 16 | $374 | $23 |
| Losartan | 27 | $267 | $10 |
| Clopidogrel | 19 | $260 | $14 |
| Amlodipine Besylate | 42 | $214 | $5 |
| Lisinopril | 21 | $174 | $8 |
| Metoprolol | 11 | $68 | $6 |
2017: 16 drugs
| Praluent | 50 | $66,116 | $1,322 |
| Repatha Sureclick | 24 | $26,340 | $1,098 |
| Atorvastatin | 140 | $3,519 | $25 |
| Rosuvastatin | 61 | $3,508 | $58 |
| Metoprolol | 23 | $1,034 | $45 |
| Chlorthalidone | 15 | $773 | $52 |
| Amlodipine Besylate | 37 | $388 | $10 |
| Losartan | 28 | $308 | $11 |
| Clopidogrel | 16 | $297 | $19 |
| Fenofibrate | 13 | $283 | $22 |
| Hydrochlorothiazide | 19 | $204 | $11 |
| Isosorbide Mononitrate Er | 12 | $184 | $15 |
| Spironolactone | 13 | $182 | $14 |
| Lisinopril | 20 | $167 | $8 |
| Benazepril | 14 | $129 | $9 |
| Metoprolol | 14 | $51 | $4 |
2016: 15 drugs
| Praluent | 14 | $16,157 | $1,154 |
| Crestor | 15 | $5,535 | $369 |
| Nexium | 11 | $3,840 | $349 |
| Atorvastatin | 96 | $2,374 | $25 |
| Chlorthalidone | 14 | $825 | $59 |
| Metoprolol | 17 | $660 | $39 |
| Amlodipine Besylate | 43 | $342 | $8 |
| Spironolactone | 17 | $280 | $16 |
| Hydrochlorothiazide | 27 | $280 | $10 |
| Cartia Xt | 13 | $245 | $19 |
| Lisinopril | 24 | $218 | $9 |
| Potassium Chloride | 11 | $176 | $16 |
| Losartan | 15 | $166 | $11 |
| Benazepril | 13 | $68 | $5 |
| Furosemide | 12 | $28 | $2 |
2015: 9 drugs
| Atorvastatin | 70 | $1,541 | $22 |
| Metoprolol | 26 | $754 | $29 |
| Irbesartan | 14 | $300 | $21 |
| Carvedilol | 18 | $197 | $11 |
| Spironolactone | 18 | $154 | $9 |
| Hydrochlorothiazide | 15 | $154 | $10 |
| Amlodipine Besylate | 18 | $118 | $7 |
| Metoprolol | 12 | $101 | $8 |
| Lisinopril | 15 | $99 | $7 |
2014: 4 drugs
| Atorvastatin | 33 | $844 | $26 |
| Irbesartan | 12 | $448 | $37 |
| Warfarin | 16 | $122 | $8 |
| Amlodipine Besylate | 11 | $73 | $7 |
2013: 9 drugs
| Crestor | 25 | $5,360 | $214 |
| Atorvastatin | 48 | $3,204 | $67 |
| Diovan Hct | 12 | $1,482 | $124 |
| Metoprolol | 16 | $1,242 | $78 |
| Ramipril | 13 | $803 | $62 |
| Diltiazem 24hr Er | 12 | $621 | $52 |
| Warfarin | 21 | $242 | $12 |
| Simvastatin | 13 | $198 | $15 |
| Losartan | 11 | $113 | $10 |
Money from drug and device companies
$13,032 in 2025
| 2025 | 5 | 9 | $12,707 | $13,032 |
| 2024 | 1 | 1 | $793 | $793 |
| 2023 | 3 | 9 | $4,779 | $7,893 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
Ablative Solutions, Inc.
$3,578
Held by this doctor · 2023 · Stock Warrant Granted. · amount invested $14,312
Published ownership or investment in a drug or device company. This is not proof that care is biased.
A payment is not proof that care is biased.
| Heartflow | Ffrct | $6,600 | 3 payments
|
| Bayer Healthcare | None | $3,505 | 2 payments
|
| Abiomed | None | $2,750 | 2 payments
|
| Merck Sharp & Dohme | None | $125 | 1 payment
|
| Idorsia Pharmaceuticals US | Tryvio | $52 | 1 payment
|
See all 9 published payments
| Bayer Healthcare | Consulting · 2025-11-09 | None | $3,357 |
| Bayer Healthcare | Meals · 2025-11-09 | None | $148 |
| Merck Sharp & Dohme | Meals · 2025-11-08 | None | $125 |
| Heartflow | Consulting · 2025-10-29 | Ffrct | $2,000 |
| Heartflow | Consulting · 2025-10-16 | Ffrct | $1,600 |
| Heartflow | Consulting · 2025-08-20 | Ffrct | $3,000 |
| Idorsia Pharmaceuticals US | Education · 2025-08-06 | Tryvio | $52 |
| Abiomed | Consulting · 2025-04-17 | None | $2,250 |
| Abiomed | Consulting · 2025-02-05 | None | $500 |
See earlier years (2024, 2023)
2024: $793
| Regeneron Pharmaceuticals | None | $793 | 1 payment
|
2023: $7,893
| Cleerly | None | $2,973 | 3 payments
|
| Regeneron Pharmaceuticals | None | $2,520 | 5 payments
|
| Scilex Pharmaceuticals | Gloperba | $2,400 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Cleerly, Inc. · Transform · 2024 | Their institution | $243,000 |
| Cleerly, Inc. · Transform · 2025 | Their institution | $162,000 |
| Genentech, Inc. · Phase 1c Selnoflast Proof of Concept · 2024 | Their institution | $98,542 |
| AstraZeneca Pharmaceuticals LP · A Multinational Randomised Double Blind Placebo Controlled Trial To Evaluate the Effect of Ticagrelor 90 Mg Twice Daily on the Incidence of Cardiovascular Death Myocardial Infarction Or Stroke in Patients With Type 2 Diabetes · 2019 | Their institution | $7,544 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1538251962
- Licence
- CA G48267, TN MD24919California G48267: Current · expires 2027-11-30Tennessee 24919: Voluntarily Retired
- Trained
- University of Southern California Keck School of Medicine, 1981
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-09-30
- NPI last updated
- 2024-04-23
- NPI record certified
- 2024-04-23
This is when the NPI record was last certified, not a medical board exam.